TABLE 2.
Immunogena | Injection no. | Geometric mean (range) (ELISA units)b
|
|
---|---|---|---|
IgG | IgM | ||
dLOS-TT | 1 | 1 (1-2) | 4 (2-5) |
2 | 21 (2-267) | 6 (3-10) | |
3 | 162 (24-1,074)c | 15 (4-51) | |
dLOS-CRM-1 | 1 | 1 | 3 |
2 | 19 (5-84) | 4 (2-8) | |
3 | 115 (65-202)c | 13 (6-29) | |
dLOS-CRM-2 | 1 | 1 | 3 (3-5) |
2 | 8 (2-26) | 6 (1-28) | |
3 | 95 (16-572)c | 21 (6-68) | |
dLOS-TT, Ribi | 1 | 2 (1-3) | 8 (5-11) |
2 | 491 (65-3,685) | 7 (3-18) | |
3 | 1,718 (171-17,212)c | 15 (2-98) | |
dLOS-CRM-1, Ribi | 1 | 2 (1-5) | 6 (3-10) |
2 | 947 (88-10,253) | 18 (3-110) | |
3 | 1,887 (300-11,862)c | 14 (5-39) | |
dLOS-CRM-2, Ribi | 1 | 4 (2-6) | 7 (4-11) |
2 | 2,558 (295-22,191) | 36 (10-132) | |
3 | 3,050 (1,244-7,479)c | 20 (12-33) | |
dLOS, CRM, TT, Ribi | 1 | 1 (1-4) | 2 (1-3) |
2 | 2 (1-5) | 2 (1-5) | |
3 | 5 (4-7) | 2 (1-4) |
Eight mice in each group were given a total of three subcutaneous injections at 3-week intervals consisting of 5 μg of conjugates (sugar content), conjugates with Ribi adjuvant, or a mixture of dLOS, TT, CRM, and Ribi adjuvant (5 μg of each). Blood samples were collected 2 weeks after each injection.
The number of ELISA units was based on the data obtained with a mouse reference serum against strain 26404, and the LOS from strain 26404 was used as a coating antigen.
P < 0.01 for a comparison with the corresponding group after one injection.